Aarti Drugs' Debt Ratings Affirmed by ICRA at Strong Levels

ICRA Limited has reaffirmed Aarti Drugs Limited's credit ratings, covering total debt worth ₹1,452.80 crore. The long-term debt is rated '[ICRA] AA- (Stable)', and short-term debt '[ICRA] A1+'.

What Happened

ICRA Limited announced on March 24, 2026, its decision to reaffirm the credit ratings for Aarti Drugs Limited's various debt instruments. The long-term fund-based term loans and credit facilities totaling ₹367.80 crore have been assigned '[ICRA] AA- (Stable)'. Simultaneously, the company's short-term fund-based and non-fund based facilities amounting to ₹1,085.00 crore have been reaffirmed at '[ICRA] A1+'. These ratings cover a significant total debt value of ₹1,452.80 crore.

Why this matters

This rating reaffirmation is a strong endorsement of Aarti Drugs' creditworthiness and financial stability. It reassures lenders and investors that the company has a solid financial footing and is capable of meeting its debt obligations. This is crucial for maintaining access to debt capital at potentially favourable interest rates, supporting ongoing operations and future growth plans.

Background

Aarti Drugs, a prominent Indian pharmaceutical company, specializes in manufacturing Active Pharmaceutical Ingredients (APIs) and intermediates. In February 2023, ICRA had previously reaffirmed Aarti Drugs' ratings for debt totaling ₹922.80 crore at '[ICRA] AA- (Stable)' and '[ICRA] A1+'. Prior to that, in August 2021, ratings for debt aggregating ₹663.10 crore were reaffirmed at similar levels. The current reaffirmation covers a significantly larger debt amount of ₹1,452.80 crore, indicating an expansion in the company's financing base or scale.

What This Means

• Continued access to debt markets with potentially competitive borrowing costs.
• Enhanced lender confidence in Aarti Drugs' financial health.
• Support for ongoing operational requirements and potential expansion projects.
• Reinforcement of the company's stable credit profile among peers.

Risks to watch

ICRA reserves the right to review and revise these ratings if circumstances change significantly, such as adverse financial performance or lack of necessary information. Any regulatory restrictions imposed on the company could also trigger a rating review.

Peer comparison

Aarti Drugs operates within the pharmaceutical sector, which includes companies like Divi's Laboratories, Lupin, and Torrent Pharmaceuticals. Divi's Laboratories consistently maintains high credit ratings, often in the AAA category, reflecting its robust financial performance and market dominance in APIs. Lupin and Torrent Pharmaceuticals typically hold investment-grade ratings, indicative of strong financial management within the competitive Indian pharmaceutical landscape.

What to track next

• The company's ongoing adherence to the covenants and terms of the rated debt instruments.
• Future financial performance reports and ICRA's surveillance reviews.
• Any significant changes in the company's debt structure or capital expenditure plans.
• Developments in the broader pharmaceutical and API market that could influence the company's profitability and cash flows.